Skip to content

Investigating the injection of adipose tissue stromal vascular cells in the treatment of psoriasis

Investigating the safety and effectiveness of intradermal injection of stromal vascular fraction cells (SVF) of autologous adipose tissue in the treatment of patients with plaque type psoriasis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200127046282N38
Enrollment
10
Registered
2024-06-08
Start date
2024-06-14
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Psoriasis

Interventions

Intervention 1: Intervention group: stromal vascular fraction cells (extracted from 50 cc of fat tissue) will be injected intradermally once. Intervention 2: Control group: In another lesion, normal s

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of psoriasis Absence of infection and malignancy Discontinuation of topical treatment at least two weeks in advance, and in the case of patients who benefit from systemic treatment, discontinuation of antipsoriasis drugs one month in advance.

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Allergy and sensitivity to the ingredients in the formulation

Design outcomes

Primary

MeasureTime frame
Skin redness. Timepoint: Week 0 and 6 months after the last treatment session. Method of measurement: 1-Standard psoriasis evaluation questionnaire 2-Questionnaire for evaluating the quality of life of patients with psoriasis 3-Photos of patients before, during and after treatment 4-Using a measurement device.;Thickness. Timepoint: Week 0 and 6 months after the last treatment session. Method of measurement: 1-Standard psoriasis evaluation questionnaire 2-Questionnaire for evaluating the quality of life of patients with psoriasis 3-Photos of patients before, during and after treatment 4-Using a measurement device.;Flaking. Timepoint: Week 0 and 6 months after the last treatment session. Method of measurement: 1-Standard psoriasis evaluation questionnaire 2-Questionnaire for evaluating the quality of life of patients with psoriasis 3-Photos of patients before, during and after treatment 4-Using a measurement device.;Level of conflict. Timepoint: Week 0 and 6 months after the last treatment session. Method of measurement: 1-Standard psoriasis evaluation questionnaire 2-Questionnaire for evaluating the quality of life of patients with psoriasis 3-Photos of patients before, during and after treatment 4-Using a measurement device.;Pasi. Timepoint: Week 0 and 6 months after the last treatment session. Method of measurement: Using a measuring device.;Photography of waste. Timepoint: Week 0 and 6 months after the last treatment session. Method of measurement: Photos of patients before, during and after treatment.

Secondary

MeasureTime frame
Side effects (systemic and local). Timepoint: All patients have been given a phone number that they can call during and after the treatment if needed and report any side effects caused by the medicine. Method of measurement: All patients have been given a phone number that they can call during and after the treatment if needed and report any side effects caused by the medicine.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Skin and Stem Cell Research Center of Tehran University of Medical Sciences

sonazarebio@gmail.com+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026